Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917294 | 0.89 | CHRNB2 (0.38) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL2918633 | 0.83 | POLB (0.36) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL7787553 | 0.81 | KMT2A (0.34) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL9053082 | 0.80 | L3MBTL1 (0.36) | — | |
| SCHEMBL5661852 | 0.80 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL715395 | 0.78 | — | — | |
| SCHEMBL7786231 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL4984 | 0.77 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL3914034 | 0.77 | — | — | |
| SCHEMBL3556319 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-0775132-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 1997-05-28 | — | — | EP | claimed |
| EP-0438230-B1 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME (GB) | 1997-04-23 | — | — | EP | claimed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | claimed |
| EP-2007733-B1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | disclosed |
| EP-0438230-B1 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME (GB) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| US-5317103-A | Migraine treatment | MERCK SHARP & DOHME LIMITED (GB) | 1994-05-31 | — | — | US | disclosed |
| US-5208248-A | Hydroxytryptamine Receptor Agonists | MERCK SHARPE & DOHME, LTD. (GB) | 1993-05-04 | — | — | US | disclosed |
| EP-0494774-A1 | Indazole-substituted fivemembered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1992-07-15 | — | — | EP | disclosed |
| EP-0438230-A2 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | CHRNB2 4674/4885CHRNA4 4657/4885CHRNA7 4373/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | CHRNB2 2161/4885CHRNA4 2476/4885CHRNA7 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.